

HGF和VEGFR-3在大肠癌中的表达及其在淋巴管生成和转移中的作用

熊枝繁,于欢,曹仕琼,曾劲,熊亮

430077 武汉,华中科技大学同济医学院附属梨园医院消化内科

Expression of HGF and VEGFR-3 in Colorectal Carcinoma and Their Role in Lymphangiogenesis and Lymphatic Metastasis

XIONG Zhi-fan, YU Huan, CAO Shi-qiong, ZENG Jin, XIONG Liang

Department of Digestion, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430077, China

- 摘要
- 参考文献
- 相关文章

全文: PDF (1906 KB) HTML (0 KB) 输出: BibTeX | EndNote (RIS) 背景资料

服务

把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS

作者相关文章

熊枝繁
于欢
曹仕琼
曾劲
熊亮

摘要 目的

观察肝细胞生长因子(HGF)和血管内皮生长因子受体3(VEGFR-3)在大肠癌组织中的表达,检测大肠癌组织中的微淋巴管密度(LMVD),探讨HGF和VEGFR-3在大肠癌淋巴管生成及转移中的作用。

方法

应用免疫组织化学(SABC)法检测52例大肠癌、20例大肠息肉组织和20例健康对照组织中HGF和VEGFR-3的表达,并应用podoplanin标记淋巴管,检测各组组织中的淋巴管密度,结合大肠癌患者的临床病理资料,分析其相关性。

结果

(1)大肠癌组织中HGF和VEGFR-3均被染成棕褐色或棕黄色,阳性表达率分别为75%、67.3%,相对表达量分别为(0.36±0.07)、(0.41±0.10),均明显高于大肠息肉组[25%、30%;(0.24±0.06)、(0.28±0.03)]和正常大肠组织[15%、10%;(0.23±0.06)、(0.21±0.03)]的表达($P < 0.01$)。且微淋巴管密度(LMVD)也明显增多[(4.13±1.99) vs. (2.59±1.46) vs. (2.40±1.44), $P < 0.01$]。(2)大肠癌组织中HGF、VEGFR-3的相对表达量,LMVD三者间呈两两正相关。39例HGF表达阳性的大肠癌,其LMVD明显大于HGF表达阴性者[(4.25±2.13) vs. (2.73±1.54), $t=3.051$, $P=0.003$];35例VEGFR-3表达阳性的大肠癌,其LMVD也明显大于VEGFR-3表达阴性者[(3.79±1.26) vs. (2.64±1.32), $t=3.235$, $P=0.002$]。(3)HGF、VEGFR-3和LMVD的表达与大肠癌患者年龄、性别以及肿瘤分化程度无关($P > 0.05$),但与Dukes分期($P=0.034$, $P=0.021$, $P=0.006$)、淋巴管有无转移明显相关($P=0.015$, $P=0.012$, $P=0.001$)。

结论

HGF与大肠癌的淋巴管生成及转移有一定的相关性,并可能通过VEGF-C、D/VEGFR-3信号途径间接促进淋巴管增生,从而促进肿瘤细胞的淋巴转移。

关键词: 大肠癌 肝细胞生长因子 血管内皮生长因子受体3 微淋巴管密度

Abstract: Objective

To investigate the role of hepatocyte growth factor(HGF) and vascular endothelial growth factor receptor 3(VEGFR-3) in lymphangiogenesis and lymphatic metastasis of colorectal carcinoma by analyzing the expression of HGF and VEGFR-3, and calculating lymphatic vessel density (LMVD) in colorectal carcinoma.

Methods

The expression of HGF and VEGFR-3 in specimens of 52 colorectal carcinoma, 20 colorectal polyps tissues and 20 colorectal normal tissues was evaluated by immunohistochemistry utilizing streptavidin biotin complex. LMVD in colorectal carcinoma was calculated by using podoplanin as the specific marker of lymphatic endothelium. And the clinicopathological features of colorectal carcinoma were analyzed.

Results

(1) The stainings of brown and filamentous in cytoplasm were observed as the positive expression of HGF and

VEGFR-3 proteins. The positive rate(75% , 67.5%) and mean value [(0.36 ± 0.07), (0.41 ± 0.10)] of HGF and VEGFR 3 expressions in specimens of colorectal carcinoma were significantly higher than those of the colorectal polyps tissues[25%,30%; (0.24 ± 0.06),(0.28 ± 0.03)] and the normal bowel tissues(15% 10%; 0.23 ± 0.06 0.21 ± 0.03)(P < 0.05). The LMVD of colorectal carcinoma was also significantly higher than those of the colorectal polyps tissues and the normal bowel tissues [(4.13 ± 1.99) vs. (2.59 ± 1.46) vs. (2.40 ± 1.44), P < 0.01]. (2) A significant correlation was found between either two of LMVD, the mean value of HGF and VEGFR 3 in specimens of colorectal carcinoma. The positive expression of HGF was found in 39 cases of colorectal carcinoma, and their mean LMVD was higher than that in the negative ones [(4.25 ± 2.13) vs. (2.73 ± 1.54), t= 3.051 , P = 0.003]. The positive expression of VEGFR 3 was observed in 35 cases of colorectal carcinoma, and their mean LMVD was higher than that in the negative ones [(3.79 ± 1.26) vs. (2.64 ± 1.32), t= 3.235 ,P = 0.002]. (3) The expression of HGF, VEGFR 3 and LMVD in colorectal carcinoma was no correlation with age, gender and degree of differentiation, but significant correlation with Dukes' staging(P= 0.034 ,P= 0.021 ,P = 0.006) and lymph node metastasis(P= 0.015 ,P= 0.012 ,P = 0.001).

Conclusion

The positive expression of HGF is related with colorectal cancer lymphangiogenesis and lymphatic metastasis. It seems that HGF induces lymphangiogenesis indirectly through VEGF-C,D/VEGFR-3 signaling pathway and contributes to lymphatic metastasis in colorectal carcinoma.

Key words: **Colorectal carcinoma Hepatocyte growth factor Vascular endothelial growth factor receptor3**

Lymphatic vessel density

收稿日期: 2008-07-28;

引用本文:

熊枝繁,于欢,曹仕琼等. HGF和VEGFR-3在大肠癌中的表达及其在淋巴管生成和转移中的作用[J]. 肿瘤防治研究, 2009, 36(10): 838-843.

XIONG Zhi-fan,YU Huan,CAO Shi-qiong et al. Expression of HGF and VEGFR-3 in Colorectal Carcinoma and Their Role in Lymphangiogenesis and Lymphatic Metastasis[J]. CHINA RESEARCH ON PREVENTION AND TREATMENT, 2009, 36(10): 838-843.

没有本文参考文献

- [1] 吕慧芳;刘红亮;陈小兵;陈贝贝;李宁;邓文英;马磊;罗素霞. TIP30基因对大肠癌细胞HCT116生物学特性的影响[J]. 肿瘤防治研究, 2012, 39(1): 13-17.
- [2] 周飞;崔滨滨;刘彦龙;刘建玲;阎广真;杨钰 . usp22和ki67在大肠癌组织中的表达及其临床意义[J]. 肿瘤防治研究, 2012, 39(1): 68-70.
- [3] 杨光华;赵晶;李磊;王天阳;张小艳;吕春秀;王凤安. BAG-1在大肠癌中的表达及其临床意义[J]. 肿瘤防治研究, 2012, 39(1): 71-74.
- [4] 申兴斌;段惠佳;赵杨;张古林 . 垂体肿瘤转化基因在大肠正常黏膜、腺瘤及大肠癌组织中的表达及意义[J]. 肿瘤防治研究, 2011, 38(9): 1042-1045.
- [5] 刘培根;马利林;朱建伟. 氧化应激对大肠癌细胞迁移、血管内皮生长因子表达及细胞间通信的影响[J]. 肿瘤防治研究, 2011, 38(8): 857-860.
- [6] 陈曦;毛勤生;黄华;朱建伟. PKC-ζ在大肠良恶性组织中的表达及其与Cortactin蛋白的关系[J]. 肿瘤防治研究, 2011, 38(8): 903-908.
- [7] 吴民华;陈小毅;梁艳清 . STAT5和c-myc在大肠癌中的表达及意义[J]. 肿瘤防治研究, 2011, 38(7): 806-808.
- [8] 张雪玉;张咏梅;杨彩虹;刘莉莉;吴蔚 . HGF、c-Met和VEGF-C在宫颈癌中的表达[J]. 肿瘤防治研究, 2011, 38(4): 411-415.
- [9] 贾漪涛;刘敏;王安峰;郭薇;张雷;李中信 . 肝细胞生长因子对结肠癌细胞SW620增殖、侵袭的影响[J]. 肿瘤防治研究, 2011, 38(4): 377-379.
- [10] 周莉;侯安继. ATP生物荧光技术指导大肠癌患者腹腔化疗的研究 [J]. 肿瘤防治研究, 2011, 38(11): 1280-1282.
- [11] 王杰;奉典旭;陈超;倪振华;左青松;陈亚峰;王旭;张勇;陈腾 . 蟾毒灵对裸鼠大肠癌原位移植瘤的抗肿瘤作用及其对凋亡相关基因Bcl-xL、Bax表达的影响 [J]. 肿瘤防治研究, 2011, 38(10): 1121-1125.
- [12] 庞雅青;马杰;魏冰;孙喜斌;许林平;买玲. 食管小细胞癌中Survivin、NF-κB、VEGF-C 的表达及其与MVD、MLVD的相关性[J]. 肿瘤防治研究, 2010, 37(12): 1383-1386.
- [13] 吴潼;赵静;赵小娟;高志芹;于文静;冯曼;连波. 血管生成素及其受体在大肠癌中的表达及其与肿瘤血管生成的关系[J]. 肿瘤防治研究, 2010, 37(12): 1400-1403.
- [14] 吴爱国;焦得闯;李鹏;邵国利;纪术峰;韩明阳. Trastuzumab F(ab')2修饰紫杉醇免疫脂质体对人大肠癌HT-29细胞的杀伤作用[J]. 肿瘤防治研究, 2010, 37(12): 1360-1363.
- [15] 萧剑军;彭杰文;贺景焕;江小梅;何洁冰. 晚期大肠癌患者化疗前后T淋巴细胞亚群检测的临床价值[J]. 肿瘤防治研究, 2010, 37(08): 931-934.